Tarsus Pharmaceuticals shows strong execution as Xdemvy sales now exceed marketing expenses. The biotech company's aggressive push for its Demodex blepharitis treatment is delivering results, signaling successful market penetration. The appointment of David Pyott, former Allergan CEO, to the board strengthens leadership credibility. TARS has significant clinical catalysts ahead in the first half of 2027, including trials for lotilaner in Lyme disease prevention and ocular rosacea treatment. The company remains confident that TP-03/Xdemvy will achieve European regulatory approval by 2027. These developments suggest the company is transitioning from heavy investment phase to revenue generation while advancing its pipeline.
Post from MarketNews_en
Log in to interact with content.